News and Trends 3 May 2017 French Biotech gets a Second Opportunity to Fight Liver Fibrosis Genkyotex, a French biotech with an eye on NASH, has received FDA approval to initiate a Phase II trial in primary biliary cholangitis. Genkyotex’s lead candidate, GKT831, failed to prove its efficacy in a Phase II trial for diabetic nephropathy a couple of years ago. Now, the company is taking a second shot by targeting liver […] May 3, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2017 Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech Genfit is leading the race to launch the first treatment ever for non-alcoholic steatohepatitis (NASH), a liver disease that affects 30 million people worldwide and has […] April 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2017 Two Big Pharma Players Team up to Take Over the NASH Space Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining its immunomodulator and Novartis’ FXR agonist for NASH. After Allergan snapped up Tobira’s cenicriviroc (CVC) last year in a €1.4B deal, the company is now taking the next step to advance its pipeline in the Non-Alcoholic SteatoHepatitis (NASH) race. The pharma company is going […] April 18, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2017 Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market? Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy” to biotech. On July 20, 2012, the western world’s first gene therapy, Glybera, received marketing authorization from the EMA. The treatment was designed and developed by uniQure as one-off treatment for Lipoprotein Lipase Deficiency (LPLD), a […] March 28, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 French Biotech gets a Boost in the NASH Race with a Successful IPO Inventiva has completed an IPO on Euronext Paris raising €48M that will support the advancement of its pipeline, which includes big indications such as NASH. Inventiva, a drug discovery company from France, is the protagonist today of a successful biotech IPO on Euronext Paris despite the financial difficulties of past years. The company has raised €48M, which will […] February 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2017 Top European VC and CRO fund Young Metabolic Disease Biotech Eternygen has received €8M in a Series A round led by Epidarex Capital that will be used to advance its pipeline in collaboration with Evotec. Eternygen is a young biotech in Berlin focusing on the treatment of metabolic diseases. The company has now raised €8M in Series A, led by Scottish biotech VC Epidarex Capital. Among the […] January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2017 Shire sells its RNA platform to a US-based Biotech Shire has sold its RNA therapy program to a smaller biotech that wants to accelerate the development of products from the platform. The Irish drug giant Shire is giving its MRT program, which includes two mRNA platforms and 12 employees, to US-based RaNA Therapeutics. In exchange, Shire will receive an undisclosed share of equity in the biotech as well […] January 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2017 This British Biotech is buying its way into the Crowded NASH Space Tiziana Life Sciences is acquiring candidates to gain leverage in the profitable NASH market, where there’s currently a fierce competition. Tiziana Life Sciences, a biopharmaceutical company from London, is planning to enter the competitive space of non-alcoholic steatohepatitis (NASH). To gain leverage over bigger companies fighting to enter a market expected to hit a massive €38B ($40B) by […] January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Dec 2016 The Largest Deals, Fundraising and Exits of 2016 in European Biotech Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […] December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2016 “We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease” Promethera is collecting cash to fuel its liver disease program that revolves around HepaStem. I sat down with the CEO to hear more about the link between the company’s seemingly diverse interests and future direction. Promethera is the new kid on Belgium’s biotech block in Louvain-la-Neuve, and it’s hatching plans to make a splash with an IPO next spring. […] November 21, 2016 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2016 Green Light for Genfit to Tackle another Liver Disease The FDA has cleared Genfit’s IND application to treat a second liver disease with a big unmet clinical need. With this new step forward, the company gets even closer to become the leader in liver disease treatments. After a very successful fundraising last week, Genfit is kicking off the week with good news from the […] November 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2016 Novo Nordisk pressured into Dropping Needle-Free Oral Insulin Needle-free diabetes will have to wait: payers are pressuring pharma to provide lower medication prices, and Novo Nordisk has responded by redirecting its R&D strategy into more innovative research. Despite its position as a world leader in diabetes, Novo Nordisk seems to be hitting a rough patch: the big pharma is reducing its profit and […] November 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email